除了肾细胞癌,贝达药业还在开展伏罗尼布治疗其它适应症的临床试验,包括继发于病理性近视的脉络膜新生血管(mCNV)、湿性年龄相关性黄斑变性(w-AMD)、急性髓系白血病等。
参考资料:[1]国家药监局批准伏罗尼布片上市.Retrieved Jun 8,2023, From https://www.nmpa.gov.cn/yaowen/ypjgyw/20230608165801122.html[2] 贝达药业伏罗尼布片(CM082)上市申请获受理. Retrieved Jan 14,2022, from https://mp.weixin.qq.com/s/yHrneAxiUBC2OfXxkQX0XA[3]贝达药业埃克替尼和伏罗尼布临床研究成果亮相ASCO年会. Retrieved Jun 4, 2021, from https://www.bettapharma.com/News/show/id/2388
[4]贝达药业官网. From https://www.bettapharma.com/Newdrug/projects